Eli Lilly announces first human anti-body trial to treat COVID-19

Eli Lilly begins early-stage human testing of its experimental antibody-based COVID-19 vaccine

Eli Lilly and Company has begun what it calls the first study in the world for a potential COVID-19 antibody treatment for humans. The American pharmaceutical company announced its partnership with the privately held Canadian biotechnology firm in March to test antibodies as a potential cure for COVID-19.

The treatment uses an antibody created to block the spike-shaped protein structures of the coronavirus from locking on to human cells, thus neutralizing it.

"What we're doing here is taking patients with Covid, offering the opportunity to participate in a new treatment, hopefully to help them recover more quickly and uneventfully from their infection", said Dr. Mark J. Mulligan, director of the infectious-disease and vaccine-research units at NYU Langone Health, according to the newspaper.

Beyond emergency and supportive care, there are now no FDA-licensed treatment options for coronavirus disease 2019 (COVID-19), the infection caused SARS-CoV-2.

"Later this month, we will review the results of this first human study and intend to initiate broader efficacy trials".


In phase one of the study, hospitalized COVID-19 patients are being dosed at medical facilities to closely track safety and response to the treatment, with initial results expected in about one month. At the same time as we are investigating safety and efficacy, we also are starting large-scale manufacturing of this potential therapy.

The trial's first phase will test whether the therapy is safe and well-tolerated.

Lilly Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about LY-CoV555 as a potential treatment for patients with COVID-19 and reflects Lilly's current beliefs.

The current treatment candidate was chosen because it is shaped to interact with the "spike proteins" used by SARS-CoV-2 to attach to human cell surfaces, the first step in invading cells, say the investigators. The study will assess both its safety and its tolerability in patients hospitalised with Covid-19. Among other things, there can be no guarantee that LY-CoV555 will prove to be an effective treatment for COVID-19.

Related:

Comments

Latest news

Juventus 'offer Chelsea Federico Bernardeschi in exchange for Jorginho'
The Italian midfielder is wanted by former Blues boss Maurizio Sarri at Juve but has become a key part of Frank Lampard's plans. The player is only focused on Chelsea , he's resumed training and is preparing for the Premier League restart.

Google’s New Android TV Dongle Revealed in New Report
The Chromecast devices today require users to pair the dongle to the Google Home app and use their phones to control the device. Unfortunately, we still don't whether it'll have a dedicated button for Netflix and Prime video.

Russia to roll out COVID-19 drug next week
Last week, the Russian Health Care Ministry approved Avifavir as the first domestic drug for the COVID-19 treatment. The official death toll, however, has remained low, at 4,693.

United Kingdom study finds minorities at higher risk of COVID-19 death
The report concludes that the relationship between ethnicity and health is "complex" and likely to be the result of a combination of factors.

Trump says GOP is looking for new convention site
North Carolina faces an upward trend in its virus cases, reporting about 29,900 cumulative cases and 900 deaths as of Tuesday. Last week, Trump demanded that Cooper guarantee him a full-scale event or he would be forced to move the event elsewhere.

Other news